Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
Gli inibitori del recettore IIb/IIIa - Cuorediverona.it Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
GUSTO V AMI GUSTO V - Trial Schematic (n = 16,588) ST ↑, lytic eligible, < 6 h ASA No Abciximab 2 x 10 U bolus (30’) Reteplase Standard Heparin: 5,000 U bolus followed by either 800 U/hr (pts < 80 kg) or 1,000 U/hr (pts ≥ 80 kg) infusion Abciximab 2 x 5 U bolus (30’) Reteplase Low Dose Heparin: 60 U/kg bolus followed by a 7 U/kg/h infusion 1º endpoint: mortality at 30 days 2º endpoint: clinical and safety events at 30 days Lancet Lancet 2001; 2001; 357:1905-14
GUSTO V AMI Primary Endpoint: 30 Days Mortality 5.9% 5.6% % Mortality • p = 0.43 for superiority • Non-Inferiority RR 0.95 (95% CI, 0.84-1.08) Std. Reteplase (n = 8260) Abciximab + ↓ Dose Reteplase (n = 8328) Days Lancet 2001; 357:1905-14
- Page 10 and 11: Inibitori GPIIb/IIIa Artist’s con
- Page 12: Characteristics of GP IIb/IIIa Inhi
- Page 15 and 16: Patogenesi delle Sindromi Coronaric
- Page 17 and 18: Sindromi Coronariche Acute ST-segme
- Page 19: 8 16 Lancet 1997; 349:1429-35 35
- Page 22 and 23: UA/NSTEMI Beneficio solo se PCI
- Page 24 and 25: % of Patients IIb/IIIa Inhibition w
- Page 26 and 27: GP IIb/IIIa Inhibitor During Medica
- Page 28 and 29: Peterson E.D.et al.: Early use of g
- Page 30 and 31: ISAR-COOL study - Pre-procedural ou
- Page 32 and 33: CAPTURE Results by Troponin T Statu
- Page 34 and 35: GP IIb/IIIa Inhibition in Diabetics
- Page 36 and 37: Gli inibitori GP IIb/IIIa IIIa ridu
- Page 38 and 39: ESC PCI guidelines 2004 2004 Recomm
- Page 40 and 41: SCA: UA/NSTEMI L’applicazione del
- Page 42 and 43: Coronarografia in base a età e TIM
- Page 44 and 45: Sindromi Coronariche Acute ST-segme
- Page 46 and 47: Occlusive thrombus contains Fibrin
- Page 48 and 49: Abciximab Improves ST Res-90 min ST
- Page 50 and 51: RAPPORT, ISAR 2, ADMIRAL, CADILLAC
- Page 52 and 53: 5 GPIIb/IIIa inhibitors trials in P
- Page 54 and 55: BMS and abciximab display a synergi
- Page 56 and 57: Study design Inclusion Criteria: ST
- Page 58 and 59: Multi-STRATEGY MULTIcenter evaluati
- Page 62 and 63: IIb/IIIa Varie...ed eventuali
- Page 64 and 65: IIb/IIIa e PCI: Nei pazienti stabil
- Page 66: Conclusioni Glycoprotein IIb/IIIa I
GUSTO V AMI<br />
GUSTO V - Trial Schematic (n = 16,588)<br />
ST ↑, lytic eligible, < 6 h<br />
ASA<br />
No Abciximab<br />
2 x 10 U bolus (30’)<br />
Reteplase<br />
Standard Heparin:<br />
5,000 U bolus followed by e<strong>it</strong>her<br />
800 U/hr (pts < 80 kg) or<br />
1,000 U/hr (pts ≥ 80 kg) infusion<br />
Abciximab<br />
2 x 5 U bolus (30’)<br />
Reteplase<br />
Low Dose Heparin:<br />
60 U/kg bolus<br />
followed by a<br />
7 U/kg/h infusion<br />
1º endpoint: mortal<strong>it</strong>y at 30 days<br />
2º endpoint: clinical and safety events at 30 days<br />
Lancet Lancet 2001; 2001; 357:1905-14
Change language